Natazia is a brand name of dienogest/estradiol, approved by the FDA in the following formulation(s):
NATAZIA (dienogest; estradiol valerate - tablet; oral-28)
Manufacturer: BAYER HLTHCARE
Approval date: May 6, 2010
Strength(s): N/A,2MG,3MG,N/A,N/A;3MG,2MG,2MG,1MG,N/A [RLD]
Has a generic version of Natazia been approved?
No. There is currently no therapeutically equivalent version of Natazia available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Natazia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Combination compound for contraception based on natural estrogen
Patent 6,133,251
Issued: October 17, 2000
Inventor(s): Dittgen; Michael & Fricke; Sabine & Hoffmann; Herbert & Moore; Claudia & Oettel; Michael & Ostertag; Monika
Assignee(s): Jenapharm GmbH & Co. KG
The combination preparation for contraception includes a first stage of 2 to 4 first stage daily dosage portions, a second stage of two groups of second stage daily dosage portions, a third stage of 2 to 4 third stage daily dosage portions and an additional stage of 2 to 4 additional stage daily dosage portions. The first stage daily dosage portion is an effective amount of natural estrogen, the second stage daily dosage portion is an effective amount of a combination of natural estrogen and natural or synthetic gestogen, the third stage daily dosage portion is another effective amount of natural estrogen and an additional stage daily dosage portion consists of a placebo. The first group of the second stage consists of 3 to 5 daily dosage portions and the second group, 13 to 17 daily dosage portions. More of the gestogen is included in the effective amount in the second group of the second stage than in the first group. The effective amount of the natural estrogen is constant in both the first and third stages, but smaller in the third stage than in the first stage.Patent expiration dates:
- October 25, 2016✓✓✓
- October 25, 2016✓✓✓
- October 25, 2016✓✓✓
- October 25, 2016
Combination preparation for contraception based on natural estrogens
Patent 6,884,793
Issued: April 26, 2005
Inventor(s): Dittgen; Michael & Fricke; Sabine & Hoffmann; Herbert & Moore; Claudia & Oettel; Michael & Ostertag; Monika
Assignee(s): Jenapharm GmbH & Co. KG
The combination preparation for contraception includes from 2 to 4 first stage daily dosage portions each including an effective amount of at least one natural estrogen as sole active ingredient, from 16 to 22 second stage daily dosage portions each including an effective amount of a combination of at least one natural estrogen and at least one natural or synthetic gestogen as active ingredient; from 2 to 4 third stage daily dosage portions each including an effective amount of at least one natural estrogen as sole active ingredient; and from 2 to 4 final stage daily dosage portions containing a pharmaceutically acceptable placebo. The estrogen may be estradiol, an estradiol compound that is metabolized to estradiol when taken into the body, a conjugated equine estrogen or a phytoestrogen. The natural or synthetic gestogen can be natural progesterone or a synthetic gestogens, such as medroxyprogesterone acetate.Patent expiration dates:
- October 25, 2016✓✓
- October 25, 2016
Multi-phase contraceptive preparation based on a natural estrogen
Patent 8,071,577
Issued: December 6, 2011
Inventor(s): Endrikat; Jan & Duesterberg; Bernd
Assignee(s): Bayer Pharma Aktiengesellschaft
The multiphase preparation having higher contraceptive safety and reduced side effects is based on a combination of a natural oestrogen with dienogest or drospirenone. The multiphase preparation is characterized by a first phase consisting of 2 daily dose units of 3 mg of oestradiol valerate, a second phase consisting of 2 groups of daily dose units, wherein a first group is formed by 5 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least two or three times an ovulation-inhibitory dose of dienogest or drospirenone and a second group is formed by 17 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least three or four times the ovulation-inhibitory dose of dienogest or drospirenone, a third phase consisting of 2 daily dose units of 1 mg of oestradiol valerate, and a further phase consisting of 2 daily dose units of pharmaceutically acceptable placebo.Patent expiration dates:
- May 13, 2026✓✓
- May 13, 2026
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- May 6, 2013 - NEW PRODUCT
See also...
- Natazia Consumer Information (Drugs.com)
- Natazia Consumer Information (Wolters Kluwer)
- Natazia Consumer Information (Cerner Multum)
- Natazia Advanced Consumer Information (Micromedex)
- Estradiol Valerate/Dienogest Consumer Information (Wolters Kluwer)
- Dienogest and estradiol Consumer Information (Cerner Multum)
- Estradiol and dienogest Advanced Consumer Information (Micromedex)
- Estradiol valerate and dienogest Advanced Consumer Information (Micromedex)
No comments:
Post a Comment